The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules
Abstract
Morpholine is a heterocycle featured in numerous approved and experimental drugs as well as bioactive molecules. It is often employed in the field of medicinal chemistry for its advantageous physicochemical, biological, and metabolic properties, as well as its facile synthetic routes. The morpholine ring is a versatile and readily accessible synthetic building block, it is easily introduced as an amine reagent or can be built according to a variety of available synthetic methodologies. This versatile scaffold, appropriately substituted, possesses a wide range of biological activities. There are many examples of molecular targets of morpholine bioactive in which the significant contribution of the morpholine moiety has been demonstrated; it is an integral component of the pharmacophore for certain enzyme active‐site inhibitors whereas it bestows selective affinity for a wide range of receptors. A large body of in vivo studies has demonstrated morpholine's potential to not only increase potency but also provide compounds with desirable drug‐like properties and improved pharamacokinetics. In this review we describe the medicinal chemistry/pharmacological activity of morpholine derivatives on various therapeutically related molecular targets, attempting to highlight the importance of the morpholine ring in drug design and development as well as to justify its classification as a privileged structure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Vlahos, C. J., Matter, W. F., Hui, K. Y., & Brown, R. F. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37680-9 · Cited by 3,240
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Brown, D. G., & Boström, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01409 · Cited by 1,964
Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., & Williams, R. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00089-4 · Cited by 1,197
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Discovery of an α-Amino C–H Arylation Reaction Using the Strategy of Accelerated Serendipity
McNally, A., Prier, C. K., & MacMillan, D. W. C. (2011) · Science · doi:10.1126/science.1213920 · Cited by 1,034
BindingDB (2025) · PubMed · doi:10.7270/q2pc374f · Cited by 924
International Union of Pharmacology. XIII. Classification of Histamine Receptors
Hill, S. J., Ganellin, C. R., Timmerman, H., Schwartz, J. C., Shankley, N. P., Young, J. M., Schunack, W., Levi, R., & Haas, H. L. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01328-0 · Cited by 899
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895 · cited 1×
“These receptors (all subtypes being GPCRs except for 5‐HT3) play a central role in neurobiology, affecting a multitude of functions in behavior, cognition and endocrine regulation, making their modulation an important objective in drug discovery.(132) More specifically, an attempt at designing a selective 5‐HT1B antag…”
BackgroundLi, L., Whiteman, M., Guan, Y. Y., Neo, K. L., Cheng, Y., Lee, S. W., Zhao, Y., Baskar, R., Tan, C.-H., & Moore, P. K. (2008) · Circulation · doi:10.1161/circulationaha.107.753467 · Cited by 839
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812
Lévesque, D., Diaz, J., Pilon, C., Martres, M. P., Giros, B., Souil, E., Schott, D., Morgat, J. L., Schwartz, J. C., & Sokoloff, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.17.8155 · Cited by 674
The pharmacology of sigma-1 receptors.
Maurice, T., & Su, T.-P. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.001 · Cited by 654
PI 3-kinase p110β: a new target for antithrombotic therapy
Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y., et al. (2005) · Nature Medicine · doi:10.1038/nm1232 · Cited by 580
Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569
Exploring the specificity of the PI3K family inhibitor LY294002
Gharbi, S. I., Zvelebil, M. J., Shuttleworth, S. J., Hancox, T., Saghir, N., Timms, J. F., & Waterfield, M. D. (2007) · Biochemical Journal · doi:10.1042/bj20061489 · Cited by 462
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
García-Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20090489 · Cited by 455
Photoredox α-Vinylation of α-Amino Acids and N-Aryl Amines
Noble, A., & MacMillan, D. W. C. (2014) · Journal of the American Chemical Society · doi:10.1021/ja506094d · Cited by 431
An analgesia circuit activated by cannabinoids
Meng, I. D., Manning, B. H., Martin, W. J., & Fields, H. L. (1998) · Nature · doi:10.1038/26481 · Cited by 411
Leahy, J. J. J., Golding, B. T., Griffin, R. J., Hardcastle, I. R., Richardson, C., Rigoreau, L., & Smith, G. C. M. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.09.060 · Cited by 411
Wallace, M. J., Blair, R. E., Falenski, K. W., Martin, B. R., & DeLorenzo, R. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051920 · Cited by 393
Classes of phosphoinositide 3-kinases at a glance
Jean, S., & Kiger, A. A. (2014) · Journal of Cell Science · doi:10.1242/jcs.093773 · Cited by 379
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
Perzborn, E., Roehrig, S., Straub, A., Kubitza, D., & Misselwitz, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3185 · Cited by 297
D'Ambra, T. E., Estep, K. G., Bell, M. R., Eissenstat, M. A., Josef, K. A., Ward, S. J., Haycock, D. A., Baizman, E. R., & Casiano, F. M. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00079a016 · Cited by 294
Fluorine in Medicinal Chemistry
Swallow, S. (2015) · Progress in Medicinal Chemistry · doi:10.1016/bs.pmch.2014.11.001 · Cited by 280
Resistance of Morpholino Phosphorodiamidate Oligomers to Enzymatic Degradation
HUDZIAK, R. M., BAROFSKY, E., BAROFSKY, D. F., WELLER, D. L., HUANG, S.-B., & WELLER, D. D. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.267 · Cited by 275
Direct Acylation of C(sp3)−H Bonds Enabled by Nickel and Photoredox Catalysis
Joe, C. L., & Doyle, A. G. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201511438 · Cited by 267
Felder, C. C., Veluz, J. S., Williams, H. L., Briley, E. M., & Matsuda, L. A. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09174-6 · Cited by 261
Tyner, J. W., Bumm, T. G., Deininger, J., Wood, L., Aichberger, K. J., Loriaux, M. M., Druker, B. J., Burns, C. J., Fantino, E., & Deininger, M. W. (2010) · Blood · doi:10.1182/blood-2009-05-223727 · Cited by 240
Moclobemide: Therapeutic Use and Clinical Studies
Bonnet, U. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00245.x · Cited by 227
Venkatesan, A. M., Dehnhardt, C. M., Delos Santos, E., Chen, Z., Dos Santos, O., Ayral-Kaloustian, S., Khafizova, G., Brooijmans, N., Mallon, R., Hollander, I., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901830p · Cited by 216
Hale, J. J., Mills, S. G., MacCoss, M., Finke, P. E., Cascieri, M. A., Sadowski, S., Ber, E., Chicchi, G. G., Kurtz, M., Metzger, J., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980299k · Cited by 207
Pike, K. G., Malagu, K., Hummersone, M. G., Menear, K. A., Duggan, H. M. E., Gomez, S., Martin, N. M. B., Ruston, L., Pass, S. L., & Pass, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.019 · Cited by 207
Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer
Xu, L., Liu, H., Murray, B. P., Callebaut, C., Lee, M. S., Hong, A., Strickley, R. G., Tsai, L. K., Stray, K. M., Wang, Y., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000257 · Cited by 195
Hayakawa, M., Kaizawa, H., Moritomo, H., Koizumi, T., Ohishi, T., Okada, M., Ohta, M., Tsukamoto, S.-I., Parker, P., Workman, P., et al. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.06.046 · Cited by 194
C–H functionalization of amines with aryl halides by nickel-photoredox catalysis
Ahneman, D. T., & Doyle, A. G. (2016) · Chemical Science · doi:10.1039/c6sc02815b · Cited by 188
Morpholino and Phosphorothioate Antisense Oligomers Compared in Cell-Free and In-Cell Systems
SUMMERTON, J., STEIN, D., HUANG, S. B., MATTHEWS, P., WELLER, D., & PARTRIDGE, M. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.63 · Cited by 179
ZSTK474 is an ATP‐competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms
Kong, D., & Yamori, T. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00580.x · Cited by 166
The Discovery of Linezolid, the First Oxazolidinone Antibacterial Agent
Ford, C., Zurenko, G. E., & Barbachyn, M. R. (2001) · Current Drug Targets - Infectious Disorders · doi:10.2174/1568005014606099 · Cited by 161
Semba, S., Itoh, N., Ito, M., Harada, M., & Yamakawa, M. (2002) · PubMed · Cited by 157
Aminoalkylindoles: Structure-Activity Relationships of Novel Cannabinoid Mimetics
Eissenstat, M. A., Bell, M. R., D'Ambra, T. E., Alexander, E. J., Daum, S. J., Ackerman, J. H., Gruett, M. D., Kumar, V., & Estep, K. G. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00016a013 · Cited by 153
Griffin, R. J., Fontana, G., Golding, B. T., Guiard, S., Hardcastle, I. R., Leahy, J. J. J., Martin, N. M. B., Richardson, C. J., Rigoreau, L. J. M., Stockley, M. L., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049526a · Cited by 148
Bautista‐Aguilera, Ó. M., Esteban, G., Bolea, I., Nikolic, K. M., Agbaba, D., Moraleda, I., Iriepa, I., Samadi, A., Soriano, E., Unzeta, M., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.12.028 · Cited by 147
Díaz, J. L., Cuberes, R., Berrocal, J., Contijoch, M., Christmann, U., Fernández, A., Port, A., Holenz, J., Buschmann, H., Laggner, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3007323 · Cited by 140
Revealing quinquennial anticancer journey of morpholine: A SAR based review
Arshad, F., Khan, M. F., Akhtar, W., Alam, M. M., Nainwal, L. M., Kaushik, S. K., Akhter, M., Parvez, S., Hasan, S. M., & Shaquiquzzaman, M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.015 · Cited by 138
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold
Knight, Z. A., Chiang, G. G., Alaimo, P. J., Kenski, D. M., Ho, C., Coan, K., Abraham, R. T., & Shokat, K. M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.06.022 · Cited by 137
Pharmacology of neuromuscular blocking drugs
Appiah-Ankam, J., & Hunter, J. M. (2004) · Continuing Education in Anaesthesia Critical Care & Pain · doi:10.1093/bjaceaccp/mkh002 · Cited by 137
McKillop, D., Hutchison, M., Partridge, E. A., Bushby, N., Cooper, C. M. F., Clarkson-Jones, J. A., Herron, W., & Swaisland, H. C. (2004) · Xenobiotica · doi:10.1080/00498250400009171 · Cited by 130
Wang, X., Wei, Z., Wu, G., Wang, J., Zhang, Y., Li, J., Zhang, H., Xie, X., Wang, X., Wang, Z.-H., et al. (2012) · Antiviral Therapy · doi:10.3851/imp2152 · Cited by 128
PI3K/mTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells
Kolev, V. N., Wright, Q. G., Vidal, C. M., Ring, J. E., Shapiro, I. M., Ricono, J. M., Weaver, D. T., Padval, M. V., Pachter, J. A., & Xu, Q. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1223 · Cited by 127
Scott, W. J., Hentemann, M. F., Rowley, R. B., Bull, C. O., Jenkins, S., Bullion, A. M., Johnson, J. S., Redman, A. M., Robbins, A. H., Esler, W. P., et al. (2016) · ChemMedChem · doi:10.1002/cmdc.201600148 · Cited by 127
Ohui, K. A., Afanasenko, E., Bacher, F., Ting, R. L. X., Zafar, A., Blanco‐Cabra, N., Torrents, E., Dömötör, O., May, N. V., Darvasiová, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01031 · Cited by 126
GYY4137, a Novel Water-Soluble, H2S-Releasing Molecule
Rose, P. E., Dymock, B. W., & Moore, P. K. (2015) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2014.11.014 · Cited by 119
An anti-inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model
Duan, W., Datiles, A. M. K. A., Leung, B. P. L., Vlahos, C. J., & Wong, W. S. F. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2004.10.015 · Cited by 111
Su, T., Wu, X. Z., Cone, E. J., Shukla, K. L., Gund, T., Dodge, A. L., & Parish, D. W. (1991) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20283-x · Cited by 110
Zask, A., Kaplan, J. A., Verheijen, J. C., Richard, D. J., Curran, K. J., Brooijmans, N., Bennett, E. M., Toral‐Barza, L., Hollander, I. J., Ayral‐Kaloustian, S., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901415x · Cited by 101
New class of potent ligands for the human peripheral cannabinoid receptor
Gallant, M., Dufresne, C., Gareau, Y., Guay, D., Leblanc, Y., Prasit, P., Rochette, C., Sawyer, N., Slipetz, D. M., Tremblay, N. M., et al. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00426-x · Cited by 101
Pasquier, B., El‐Ahmad, Y., Filoche-Rommé, B., Dureuil, C., Fassy, F., Abécassis, P.-Y., Mathieu, M., Bertrand, T., Bénard, T., Barrière, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5013352 · Cited by 98
Luescher, M. U., & Bode, J. W. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201505167 · Cited by 87
Cotten, J. F., Keshavaprasad, B., Laster, M. J., Eger, E. I., & Yost, C. S. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000194289.34345.63 · Cited by 85
Chrysselis, M. C., Rekka, E. A., & Kourounakis, P. N. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm991039l · Cited by 83
Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature
Castagna, D., Budd, D. C., Macdonald, S. J. F., Jamieson, C., & Watson, A. J. B. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01599 · Cited by 83
Frost, J. M., Dart, M. J., Tietje, K. R., Garrison, T. R., Grayson, G. K., Daza, A. V., El-Kouhen, O. F., Miller, L. N., Li, L., Yao, B. B., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7011613 · Cited by 82
Özil, M., Parlak, C., & Baltaş, N. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.12.019 · Cited by 81
Gris, G., Portillo-Salido, E. F., Aubel, B., Darbaky, Y., Deseure, K. R., Vela, J. M., Merlos, M., & Zamanillo, D. (2016) · Scientific Reports · doi:10.1038/srep24591 · Cited by 79
Choi, J. W., Kim, S., Park, J., Kim, H. J., Shin, S. J., Kim, J. W., Woo, S. Y., Lee, C.-H., Han, S. M., Lee, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01527 · Cited by 75
VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
Hart, S., Novotny‐Diermayr, V., Goh, K. C., Williams, M. R. V., Tan, Y. C., Ong, L. C., Cheong, A., Ng, B. K., Amalini, C., Madan, B., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0466 · Cited by 74
Newer and Older Monoamine Oxidase Inhibitors: A Comparative Profile
Laux, G., Volz, H., & Möller, H. (1995) · CNS Drugs · doi:10.2165/00023210-199503020-00006 · Cited by 69
Synthesis and Activity of a Novel Series of 3-Biarylquinuclidine Squalene Synthase Inhibitors
Brown, G. R., Clarke, D. S., Foubister, A. J., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950907l · Cited by 67
4-Phenoxypiperidines: Potent, Conformationally Restricted, Non-Imidazole Histamine H3 Antagonists
Dvorak, C. A., Apodaca, R. L., Barbier, A., Berridge, C. W., Wilson, S. J., Boggs, J. D., Xiao, W., Lovenberg, T. W., & Carruthers, N. I. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049212n · Cited by 65
Novel Benzoxazine and Benzothiazine Derivatives as Multifunctional Antihyperlipidemic Agents
Matralis, A. N., Katselou, M. G., Nikitakis, A., & Kourounakis, A. P. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200763k · Cited by 65
Self-citationStructure, conformation, and action of neuromuscular blocking drugs †
Lee, C. (2001) · British Journal of Anaesthesia · doi:10.1093/bja/87.5.755 · Cited by 64
Clinical Pharmacokinetics of the Monoamine Oxidase-A Inhibitor Moclobemide*
Mayersohn, M., & Guentert, T. W. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529050-00002 · Cited by 62
In vitrometabolism of gefitinib in human liver microsomes
McKillop, D., McCormick, A., Miles, G. S., Phillips, P. J., Pickup, K., Bushby, N., & Hutchison, M. (2004) · Xenobiotica · doi:10.1080/02772240400015222 · Cited by 61
Zheng, J., Xin, Y., Zhang, J., Subramanian, R., Murray, B. P., Whitney, J. A., Warr, M. R., Ling, J. R., Moorehead, L., Kwan, E., et al. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.078899 · Cited by 61
Mathew, B., Baek, S. C., Parambi, D. G. T., Lee, J. P., Mathew, G. E., Jayanthi, S., Devaraji, V., Rapheal, C., Devikrishna, V., Kondarath, S. S., et al. (2019) · Archiv der Pharmazie · doi:10.1002/ardp.201800309 · Cited by 61
Cano, C., Saravanan, K., Bailey, C., Bárdos, J. I., Curtin, N. J., Frigerio, M., Golding, B. T., Hardcastle, I. R., Hummersone, M., Menear, K. A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400915j · Cited by 60
Pharmacology of pravadoline: a new analgesic agent.
Haubrich, D. R., Ward, S. J., Baizman, E. R., et al. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23103-2 · Cited by 60
A dystrophic Duchenne mouse model for testing human antisense oligonucleotides
Veltrop, M. H. A. M., de Vliet, L. V., Hulsker, M., Claassens, J. W. C., Brouwers, C. M., Breukel, C., van der Kaa, J., Linssen, M. M. L., den Dunnen, J. T., Verbeek, S. J., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193289 · Cited by 60
Liu, D., Xu, Y., Yu, F., Liu, H., Shen, X., Chen, K., Ma, J., & Jiang, H. (2006) · Biochemistry · doi:10.1021/bi060955f · Cited by 59
Giblin, G. M. P., Billinton, A., Briggs, M. A., Brown, A. J., Chessell, I. P., Clayton, N. M., Eatherton, A. J., Goldsmith, P., Haslam, C. P., Johnson, M. R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9009857 · Cited by 56
Rizzoli, S. O., & Betz, W. J. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10680.2002 · Cited by 56
Singh, P., Kaur, S., Sharma, A., Kaur, G., & Bhatti, R. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.003 · Cited by 54
Zhao, Y., Liu, Y., Zhang, W., Xue, J., Wu, Y., Xu, W., Liang, X., Chen, T., Kishimoto, C., & Yuan, Z. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.027 · Cited by 50
Shim, J., Collantes, E. R., Welsh, W. J., Subramaniam, B., Howlett, A. C., Eissenstat, M. A., & Ward, S. J. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980305c · Cited by 47
Design, synthesis and DNA-binding study of some novel morpholine linked thiazolidinone derivatives
War, J. A., Srivastava, S. K., & Srivastava, S. K. (2016) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2016.07.054 · Cited by 45
Díaz, J. L., Christmann, U., Fernández, A., Torrens, A., Port, A., Pascual, R., Álvarez, I., Burgueño, J., Monroy, X., Montero, A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501920g · Cited by 44
Behavioral Pharmacology of AR-A000002, a Novel, Selective 5-Hydroxytryptamine1B Antagonist
Hudzik, T. J., Yanek, M., Porrey, T., Evenden, J. L., Paronis, C. A., Mastrangelo, M., Ryan, C. N., Ross, S. B., & Stenfors, C. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045468 · Cited by 43
Jindakun, C., Hsieh, S., & Bode, J. W. (2018) · Organic Letters · doi:10.1021/acs.orglett.8b00611 · Cited by 43
Takeuchi, H., Yatsugi, S., Hatanaka, K.-I., et al. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)10108-x · Cited by 40
Fells, J. I., Lee, S. Ç., Fujiwara, Y., Norman, D. D., Lim, K. G., Tsukahara, R., Liu, J., Patil, R., Miller, D. D., Kirby, R. J., et al. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.087080 · Cited by 40
Hatanaka, K.-I., Nomura, T., Hidaka, K., Takeuchi, H., Yatsugi, S., Fujii, M., & Yamaguchi, T. (1996) · Neuropharmacology · doi:10.1016/s0028-3908(96)00079-2 · Cited by 38
Kourounakis, A. P., Katselou, M. G., Matralis, A. N., Ladopoulou, E. M., & Bavavea, E. I. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797287557 · Cited by 38
Self-citationSisko, J. T., Tucker, T. J., Bilodeau, M. T., Buser, C. A., Ciecko, P. A., Coll, K. E., Fernandes, C., Gibbs, W. W., Koester, T. J., Kohl, N. E., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.11.089 · Cited by 36
Rosborough, B. R., Regué, D. R., Liu, Q., Venkataramanan, R., Turnquist, H. R., & Thomson, A. W. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12799 · Cited by 32
Design of more potent squalene synthase inhibitors with multiple activities
Kourounakis, A. P., Matralis, A. N., & Nikitakis, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.09.008 · Cited by 31
Self-citationDiscovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2
Pike, K. G., Morris, J. J., Ruston, L., Pass, S. L., Greenwood, R. D. R., Williams, E. J., Demeritt, J., Culshaw, J. D., Gill, K., Pass, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501778s · Cited by 31
Blockade of sigma 1 receptors alleviates sensory signs of diabetic neuropathy in rats
Paniagua, N. A., Girón, R., Goicoechea, C., López‐Miranda, V., Vela, J. M., Merlos, M., & Fontelles, M. I. M. (2016) · European Journal of Pain · doi:10.1002/ejp.897 · Cited by 25
Tong, Y., Huang, H., Jiaping, Z., Guoliang, S., & Hong-ying, P. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.045 · Cited by 24
VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo
Shao, Z., Bao, Q., Jiang, F., Qian, H., Fang, Q., & Hu, X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132655 · Cited by 23
Timolol metabolism in man and laboratory anamals.
Tocco, D. J., Duncan, A. E., Deluna, F. A., Smith, J. L., Walker, R. W., & VandenHeuvel, W. J. A. (1980) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)00263-6 · Cited by 23
New 1,5-benzodiazepine compounds: activity at native GABAA receptors
Gatta, E., Cupello, A., Braccio, M. D., Grossi, G., Ferruzzi, R., Roma, G., & Robello, M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.013 · Cited by 22
Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists
Micheli, F., Cremonesi, S., Semeraro, T., Tarsi, L., Tomelleri, S., Cavanni, P., Oliosi, B., Perdonà, E., Sava, A., Zonzini, L., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.12.081 · Cited by 22
Berry, C. B., Bubser, M., Jones, C. K., Hayes, J. P., Wepy, J. A., Locuson, C. W., Daniels, J. S., Lindsley, C. W., & Hopkins, C. R. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500267c · Cited by 22
Ladopoulou, E. M., Matralis, A. N., & Kourounakis, A. P. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400101e · Cited by 22
Self-citationPiotrowski, D. W., Futatsugi, K., Casimiro‐Garcia, A., Wei, L., Sammons, M. F., Herr, M., Jiao, W., Lavergne, S. Y., Coffey, S. B., Wright, S. W., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01515 · Cited by 21
Matralis, A. N., & Kourounakis, A. P. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00469 · Cited by 20
Self-citationZhang, M., Zhou, D., Wang, Y., Maier, D. L., Widzowski, D., Sobotka‐Briner, C. D., Brockel, B. J., Potts, W. M., Shenvi, A. B., Bernstein, P. R., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.174433 · Cited by 19
Arias, H. R., Fedorov, N. B., Benson, L. C., Lippiello, P. M., Gatto, G. J., Feuerbach, D., & Ortells, M. O. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197905 · Cited by 16
Novel orally active morpholine N-arylsulfonamides γ-secretase inhibitors with low CYP 3A4 liability
Josien, H. B., Bara, T. A., Rajagopalan, M., Clader, J. W., Greenlee, W. J., Favreau, L. V., Hyde, L. A., Nomeir, A. A., Parker, E. M., Song, L., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.055 · Cited by 14
Substituted 4-morpholine N -arylsulfonamides as γ-secretase inhibitors
Zhao, Z., Pissarnitski, D. A., Josien, H. B., Bara, T. A., Clader, J. W., Li, H., McBriar, M. D., Rajagopalan, M., Xu, R., Terracina, G., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.024 · Cited by 13
Ramirez, A., Crisafulli, S. G., Rizzuti, M., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010167 · Cited by 13
Denissen, J. F., Grabowski, B. A., Johnson, M. K., Boyd, S. A., Uchic, J. T., Stein, H. H., Cepa, S. P., & Hill, P. (1994) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08431-4 · Cited by 12
Solis, E., Suyama, J. A., Lazenka, M. F., DeFelice, L. J., Negus, S. S., Blough, B. E., & Banks, M. L. (2016) · Scientific Reports · doi:10.1038/srep31385 · Cited by 12
EP2300 Compounds: Focusing on the Antiatherosclerotic Properties of Squalene Synthase Inhibitors
Tavridou, A., & Manolopoulos, V. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789057968 · Cited by 11
Yu, W., Zou, H., Li, X., Zheng, Y., & Dong, J. (2007) · Ophthalmic Research · doi:10.1159/000111154 · Cited by 11
Disposition and metabolism of indeloxazine hydrochloride, a cerebral activator, in rats
Kamimura, H., Enjoji, Y., Sasaki, H., Kawai, R., Kaniwa, H., NIIGATA, K., & Kageyama, S. (1987) · Xenobiotica · doi:10.3109/00498258709043972 · Cited by 9
Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation
Später, T., Müller, I., Eichler, H., Menger, M. D., Laschke, M. W., & Ampofo, E. (2017) · Platelets · doi:10.1080/09537104.2017.1306040 · Cited by 8
Metadata
- Authors
- Kourounakis, A. P., Xanthopoulos, D., & Tzara, A.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2019-09-12
- Volume
- 40
- Issue
- 2
- Pages
- 709-752
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2972865283
- Cited by
- 294
- References
- 121
- FWCI
- 8.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.